Today: 30 June 2026
GE Aerospace stock price up 2.7% into weekend as 10-K filing puts engine services in focus
1 February 2026
1 min read

GE Aerospace stock price up 2.7% into weekend as 10-K filing puts engine services in focus

New York, February 1, 2026, 11:53 EST — The market has closed.

GE Aerospace shares ended Friday up 2.65%, closing at $306.79. The stock swung between $296.38 and $307.60 during the session, with roughly 7.4 million shares changing hands.

Investors head into Monday armed with fresh data from the company’s annual filing cycle, at a moment when the stock is seen as a barometer for the jet-engine service surge. On Jan. 29, GE announced it released its 2025 annual report and filed its Form 10-K with the U.S. Securities and Exchange Commission, cautioning that the filing doesn’t yet capture recent organizational shifts. The company plans to issue recast segment financials ahead of its first-quarter earnings. CEO Larry Culp emphasized the focus is “about having a great decade.” GE Aerospace

Last week, GE projected adjusted earnings per share of $7.10 to $7.40 for 2026, beating analysts’ consensus. The company is counting on strong demand for aftermarket parts and maintenance services as airlines extend the life of their planes amid ongoing delivery delays. GE’s aftermarket segment—the parts and service business post-engine delivery—generates over 70% of its commercial engine revenue, the company said.

GE surged even as Wall Street dipped Friday, following Donald Trump’s pick of Kevin Warsh for Federal Reserve chair. The Dow slipped 0.36%, while the S&P 500 dropped 0.43%.

In the CEO letter accompanying the annual report, Culp highlighted factory tweaks that boosted on-time delivery of a key LEAP engine component line to 96%, enabling a 28% ramp-up in LEAP production for 2025. He also noted, “The CFM LEAP program broke even for the first time in 2025,” adding that durability upgrades for the LEAP-1B engine are on track for certification in the first half of 2026. GE Aerospace

Engine makers are facing intensified criticism from airlines over shortages, lengthy delays for shop visits, and soaring maintenance costs. Willie Walsh, head of the International Air Transport Association, has been vocal on this issue. Bain & Company reports that turnaround times for newer-generation engine shop visits are roughly 150% longer than before the pandemic. Culp told Reuters, “We invest heavily in technology,” and insisted that prices reflect decades of support expenses. Reuters

Tension around repair capacity and “time on wing” — the duration an engine operates before requiring maintenance — is set to keep investors on edge. Even a small delay hits airline costs hard and ignites debate in the aftermarket.

Reporting also matters here. Should GE’s revised segment figures change margins or growth expectations, the market will quickly adjust its valuation, dragging peer comparisons along for the ride.

Markets are closed for the weekend, so all eyes turn to the company’s first-quarter earnings report, due April 28, per Zacks. Investors will also watch closely for updates on the LEAP durability schedule and progress addressing supply-chain bottlenecks.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Reckitt Benckiser shares jump, but an ex-dividend reset looms on Monday
Previous Story

Reckitt Benckiser shares jump, but an ex-dividend reset looms on Monday

OCBC stock price drops in Singapore as metals rout jolts markets; earnings next
Next Story

OCBC stock price drops in Singapore as metals rout jolts markets; earnings next

Go toTop